These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37537015)

  • 1. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
    Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
    Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
    Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
    Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
    Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
    Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
    Shi D; Liang X; Li Y; Chen L
    PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial.
    Zheng Z; Chen H; Cai H; Xu S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):387-395. PubMed ID: 38039117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
    Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
    Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.
    Lang Y; Wu B; Liu X
    Breast Cancer (Dove Med Press); 2022; 14():453-463. PubMed ID: 36532255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
    Yang J; Han J; Zeng N; Yan X
    Ther Adv Med Oncol; 2023; 15():17588359231169983. PubMed ID: 37228255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
    N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Wang M; Wang K; Zhu H
    Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
    Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
    Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab deruxtecan
    Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
    Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.